Management of retinal vascular diseases: A patient-centric approach

Eye (Basingstoke)

Volumn 26, Issue , 2012, Pages S1-S16

  Brand, C S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Anti VEGF therapy; Diabetic retinopathy; Individualised medicine; Retinal vein occlusion

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

BLEEDING; BLINDNESS; BREAST CANCER; COLORECTAL CANCER; DIABETIC MACULAR EDEMA; HEART INFARCTION; HUMAN; HYPERTENSION RETINOPATHY; ISCHEMIA; KIDNEY CANCER; LOADING DRUG DOSE; LUNG CANCER; MEDICAL DECISION MAKING; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; OVARY CANCER; PERITONEUM CANCER; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; SHAM FEEDING; SINGLE NUCLEOTIDE POLYMORPHISM; SLIT LAMP; STROKE; UNITED KINGDOM; VASCULAR DISEASE; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84859797655     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.32     Document Type: Article

References (78)

1. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008. Eye (Lond) 2010; 24(11): 1692–1699.
2. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999–March 2000. Eye (Lond) 2008; 22(7): 905–911.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669–676.
4. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in agerelated maculopathy. Br J Ophthalmol 1997; 81(2): 154–162.
5. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37(5): 855–868.
6. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22): 1480–1487.
7. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118(4): 445–450.
8. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002; 120(12): 1644–1650.
9. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006; 244(3): 309–315.
10. The Human Genome Project. Available at: http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml (accessed on 9 January 2011).
11. Chakravarti A. To a future of genetic medicine. Nature 2001; 409(6822): 822–823.
12. Cancer Research UK. Stratified Medicines Programme. Available at: http://science.cancerresearchuk.org/research/how-we-deliver-our-research/others/by-programme/stratified-medicine-programme/(accessed on 9 January 2011).
13. Chen Y, Bedell M, Zhang K. Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv 2010; 10(5): 271–281.
14. Issa PC, Change NV, Scholl HPN. The significance of the complement system for the pathogenesis of age-related macular degeneration – current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol 2011; 249: 163–174.
15. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vison of the future. Arch Ophthalmol 2010; 128(3): 349–358.
16. The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009 Update. Available at: http://www.rcophth.ac.uk/page.asp? section¼451§ionTitle¼ClinicalþGuidelines (accessed on 9 January 2012).
17. Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull 2008; 85: 127–149.
18. Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs 2010; 70(16): 2171–2200.
19. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. 1991; 98(5 Suppl): 766–785.
20. The Royal College of Ophthalmologists. Guidelines for diabetic retinopathy. 2005 Available at: http://www.rcophth.ac.uk/page.asp?section¼451§ionTitle ¼ClinicalþGuidelines (accessed on 9 January 2011).
21. The Royal College of Ophthalmologists. Preferred practice guidelines. Diabetic retinopathy screening (DRS) and the ophthalmology clinic set up in England. 2010. Available at: http://www.rcophth.ac.uk/page.asp?section¼451& sectionTitle¼ClinicalþGuidelines (accessed on 9 January 2012).
22. The English National Screening Programme for Diabetic Retinopathy (ENSPDR) website. Available at: http://retinalscreening.nhs.uk/pages/default.asp (accessed on 9 January 2012).
23. Aref AA, Scott IU. Management of macular edema secondary to central retinal vein occlusion: an evidence-based. Adv Ther 2011; 28(1): 40–50.
24. Aref AA, Scott IU. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. Adv Ther 2011; 28(1): 28–39.
25. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117(6): 1102–1112, e1101.
26. Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F. Retinal vein occlusion: current treatment. Ophthalmologica 2011; 225(3): 135–143.
27. Jonas J, Paques M, Mones J, Glacet-Bernard A. Retinal vein occlusions. Dev Ophthalmol 2010; 47: 111–135.
28. Kanski JJ. Retinal vascular disease. In: Clinical Ophthalmology, 5th edn. Butterworth-Heinemann: London, 2006, pp 438–486.
29. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. The Moorfields Macular Study Group. Br J Ophthalmol 1982; 66(12): 745–753.
30. European Medicines Agency. Visudyne authorisation letter. Available at: http://www.ema.europa.eu/ema/index.jsp?curl¼pages/medicines/human/medicines/000305/human_med_ 001146.jsp&mid¼WC0b01ac058001d124 (accessed on 9 January 2012).
31. TA68 Macular degeneration (age related)Fphotodynamic therapy: Guidance, 2003. Available at: http://www.nice. org.uk/nicemedia/pdf/68_PDTGuidance.pdf (accessed on 9 January 2011).
32. European Medicines Agency. Macugen authorisation letter. Available at: http://www.ema.europa.eu/ema/index.jsp?curl¼pages/medicines/human/medicines/000620/human_med_000898.jsp&mid¼WC0b01ac058001d124 (accessed on 9 January 2012).
33. European Medicines Agency. Lucentis authorisation letter. Available at: http://www.ema.europa.eu/ema/index.jsp?curl ¼pages/medicines/human/medicines/000715/human_med_000890.jsp&mid¼WC0b01ac058001d124 (accessed on 9 January 2012).
34. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432–1444.
35. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116(1): 57–65 e55.
36. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355(14): 1419–1431.
37. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145(2): 239–248.
38. Lucentis. Summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/19409 (accessed on 9 January 2012).
39. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt- Erfurth U, Wolf S et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010; 51(1): 405–412.
40. European Medicines Agency. Lucentis procedural steps taken and scientific information after the authorisation. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_ scientific_information_after_authorisation/human/000715/WC500043552.pdf (accessed on 9 January 2012).
41. DENALI study description. Available at: http://www.clinicaltrials.gov/ct2/show/record/NCT00436553?term¼NCT00436553&rank¼1 (accessed on 9 January 2012).
42. Novartis. Data on file, LUCDOF12-001. 2012.
43. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R et al. Efficacy and safety ofmonthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118(5): 831–839.
44. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118(4): 663–671.
45. MONT BLANC study description. Available at: http://clinicaltrials.gov/ct2/show/study/NCT0043301 (accessed on 9 January 2012).
46. Avastin. Summary of product characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/15748/SPC/Avastinþ25mgþmlþconcentrateþforþ solutionþforþinfusion/(accessed on 9 January 2012).
47. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897–1908.
48. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116(9): 1731–1739.
49. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103(12): 1796–1806.
50. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127(3): 245–251.
51. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341(2–3): 309–315.
52. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997; 16(4): 398–406.
53. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115(9): 1447–1449, 1449; e1441–1410.
54. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009; 116(11): 2175–2181; e2171.
55. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33(11): 2399–2405.
56. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117(6): 1064–1077 e1035.
57. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118(4): 615–625.
58. Boyer DS, Sy J, Rundle AC, Hopkins JJ, Ehrlich JS, RIDE and RISE Research Group. Ranibizumab (anti-VEGF) for vision loss due to diabetic macular edemaFresults of two phase III randomized trials. American Diabetes Association 71st Scientific Sessions. 2011. 133-LBOR.
59. Patel S, Wong P, Hopkin JJ. RISE and RIDE trials of ranibizumab for diabetic macular edema: pooled efficacy and safety analyses. American Academy of Ophthalmology. Annual Meeting, 2011. PA043.
60. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98(3): 271–282.
61. The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995; 102(10): 1425–1433.
62. Lee HB, Pulido JS, McCannel CA, Buettner H. Role of inflammation in retinal vein occlusion. Can J Ophthalmol 2007; 42(1): 131–133.
63. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127(9): 1115–1128.
64. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127(9): 1101–1114.
65. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134–1146 e1133.
66. Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Twelve month study results. Ophthalmology 2011; 118(12): 2453–2460.
67. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16(4): 791–799.
68. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147(2): 298–306.
69. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008; 115(10): 47–54.
70. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118(8): 1594–1602.
71. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118(10): 2041–2049.
72. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117(6): 1124–1133.
73. Pearce I, Gerding H, Burian G, Pilz S. Evaluation of ranibizumab treatment concept based on stability and deterioration of visual acuity in BRAVO and CRUISE patients. European Society of Retina SpecialistsF11th EURETINA Congress 2011; FP-2362.
74. Diabetes UK. Diabetes in the UK 2010: key statistics on diabetes. Available at: http://www.diabetes.org.uk/Documents/Reports/Diabetes_in_the_UK_2010.pdf (accessed on 9 January 2012).
75. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105(10): 1801–1815.
76. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361(9353): 195–200.
77. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133–141; discussion 141–133.
78. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117(2): 313–319.